Medtech company Implantica AG (Nasdaq First North Premier Growth Market:IMP A SDB) on Thursday announced the publication of a real-world study evaluating its RefluxStop device for the treatment of gastroesophageal reflux disease (GERD).
The study, conducted by Priv.-Doz. Dr. Thorsten G. Lehmann, assessed 79 patients at a leading German reflux centre.
Results published in the journal Surgery Open Science demonstrated significant improvements in both proton pump inhibitor (PPI) use and quality of life, even in patients with complex conditions, with median improvements in GERD-HRQL (Gastro-Esophageal Reflux Disease – Health-Related Quality-of-Life) score of 100% and mean improvements of 92.4%.
These findings further support the safety and efficacy of RefluxStop in treating GERD.
BD launches IVDR-certified self-collection solution to expand global access to HPV testing
Oticon launches Oticon Zeal, a discreet, fully featured in-the-ear hearing aid
Halozyme Therapeutics announces Q3 2025 release date
Samsung to invest USD110m in GRAIL and commercialise cancer detection test Galleri in Asia
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
OSR Holdings to acquire Korean non-invasive glucose monitor developer Woori IO
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Polarean Imaging signs new supply agreementwith UVA Health for clinical Xenon MRI
Femasys partners with Kebomed to expand FemBloc permanent birth control in France and Benelux
Implantica receives positive FDA feedback on final RefluxStop PMA submission